O7B

(3~{a}~{S})-2-[(3~{S})-1-azabicyclo[2.2.2]octan-3-yl]-3~{a},4,5,6-tetrahydro-3~{H}-benzo[de]isoquinolin-1-one



Chemical Component Summary

Name(3~{a}~{S})-2-[(3~{S})-1-azabicyclo[2.2.2]octan-3-yl]-3~{a},4,5,6-tetrahydro-3~{H}-benzo[de]isoquinolin-1-one
SynonymsPalonosetron; Aloxi
Identifiers(3~{a}~{S})-2-[(3~{S})-1-azabicyclo[2.2.2]octan-3-yl]-3~{a},4,5,6-tetrahydro-3~{H}-benzo[de]isoquinolin-1-one
FormulaC19 H24 N2 O
Molecular Weight296.407
TypeNON-POLYMER
Isomeric SMILESc1cc2c3c(c1)C(=O)N(C[C@H]3CCC2)[C@@H]4CN5CCC4CC5
InChIInChI=1S/C19H24N2O/c22-19-16-6-2-4-14-3-1-5-15(18(14)16)11-21(19)17-12-20-9-7-13(17)8-10-20/h2,4,6,13,15,17H,1,3,5,7-12H2/t15-,17-/m1/s1
InChIKeyCPZBLNMUGSZIPR-NVXWUHKLSA-N

Chemical Details

Formal Charge0
Atom Count46
Chiral Atom Count2
Bond Count50
Aromatic Bond Count6

Drug Info: DrugBank

DrugBank IDDB00377 
NamePalonosetron
Groups
  • investigational
  • approved
DescriptionPalonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first dose of a course of chemotherapy and is the only drug of its class approved for this use by the U.S. Food and Drug Administration. As of 2008, it is the most recent 5-HT3 antagonist to enter clinical use.
Synonyms
  • 2-(1-Azabicyclo(2.2.2)oct-3-yl)-2,3,3a,4,5,6-hexahydro-1H-benz(de)isoquinolin-1-one
  • (3aS)-2-[(3S)-1-azabicyclo[2.2.2]octan-3-yl]-2,3,3a,4,5,6-hexahydro-1H-benzo[de]isoquinolin-1-one
  • Palonosetron hydrochloride
  • Palonosetronum
  • Palonosetron
Brand Names
  • Palonosetron Hydrochloride
  • Palonosetron hydrochloride
  • Aloxi
  • Palonosetron
  • Akynzeo
IndicationFor the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy, as well as prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy. Also used for the prevention of postoperative nausea and vomiting for up to 24 hours post operation.
Categories
  • Alimentary Tract and Metabolism
  • Antidepressive Agents
  • Antiemetic Serotonin 5-HT3 Receptor Antagonists
  • Antiemetics
  • Antiemetics and Antinauseants
ATC-Code
  • A04AA55
  • A04AA05
CAS number135729-56-5

Drug Targets

NameTarget SequencePharmacological ActionActions
5-hydroxytryptamine receptor 3AMLLWVQQALLALLLPTLLAQGEARRSRNTTRPALLRLSDYLLTNYRKGVR...unknownantagonist
Cytochrome P450 2D6MGLEALVPLAVIVAIFLLLVDLMHRRQRWAARYPPGPLPLPGLGNLLHVD...unknownsubstrate
Cytochrome P450 3A4MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNI...unknownsubstrate
Cytochrome P450 1A2MALSQSVPFSATELLLASAIFCLVFWVLKGLRPRVPKGLKSPPEPWGWPL...unknownsubstrate
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682

Related Resource References

Resource NameReference
Pharos CHEMBL1189679
PubChem 6337614
ChEMBL CHEMBL1189679
ChEBI CHEBI:85161
CCDC/CSD PEXKOS01, PEXKOS